OR WAIT 15 SECS
A multi-national research team led by Duke Medicine scientists has identified a subclass of antibodies associated with an effective immune response to an HIV vaccine. The finding, reported in the March 19, 2014, issue of the journal Science Translational Medicine, helps explain why a combination of two vaccines was able to show some effect, when one vaccine alone did not. The study also provides key insights that could aid development of new vaccines.
“More is not always better with an antibody response,” says senior author Georgia D. Tomaras, PhD, director of the Laboratory of Immune Responses and Virology at Duke Human Vaccine Institute. “Instead, it’s the underlying quality of the immune response. Going forward with other vaccine trials, it will be important to know the subclass, specificity and antiviral functions of antibodies that are induced.”
Tomaras and colleagues examined two HIV vaccine trials previously conducted in Thailand. The first trial they revisited, called VAX003, was completed in 2003 and studied an investigational vaccine among intravenous drug users. The vaccine was found to be ineffective.
The second trial, known as RV144, concluded in 2009 and involved more than 16,000 adults. It used two vaccines in combination – one as the prime vaccine and the second as a boost. The boost was the same investigational vaccine used in the earlier VAX003 trial. In the RV144 study, the combination vaccine was 31.2 percent effective at preventing HIV infection – a success rate that was unprecedented, but considered too low to advance the vaccine to common use.
In both trials, the vaccines induced the production of antibodies that targeted the same region of the HIV virus. In fact, the vaccine used in the VAX003 trial actually elicited higher levels of most of the antibodies than the prime/boost combination of the more successful RV144 trial.
But there was one exception. Tomaras and colleagues found that participants in the RV144 vaccine trial were more likely to have HIV-specific IgG3 antibodies, compared to individuals in the VAX003 trial. The HIV-specific IgG3 response correlated with decreased infection risk, but the effect waned over time, similar to the declining efficacy observed in the RV144 trial.
“HIV-1 specific IgG3 is one biomarker that can be evaluated in further vaccine candidates. It provides a specific way to benchmark HIV-1 vaccine candidates against the one partially efficacious vaccine to date.” Tomaras says.
In addition to Tomaras, study authors from Duke include Nicole L. Yates, Hua-Xin Liao, Nathan A. Vandergrift, William T. Williams, S. Munir Alam, Guido Ferrari, Kelly E. Seaton, David C. Montefiori and Barton F. Haynes.
Other study authors include Youyi Fong, Allan deCamp and Peter B. Gilbert from the Fred Hutchinson Cancer Research Center; Gary Nabel and Zhi-yong Yang from the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (now at Sanofi); Phillip W. Berman of the University of California Santa Cruz; Michael D. Alpert and David T. Evans of Harvard University; Nelson L. Michael and Jerome H. Kim of the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research; Donald Francis, Faruk Sinangil, and Carter Lee of Global Solutions for Infectious Diseases; Sorachai Nitayaphan and Robert J. O’Connell of the Armed Forces Research Institute of Medical Sciences; Supachai Rerks-Ngarm of the Thailand Ministry of Public Health; Jaranit Kaewkungwal and Punnee Pitisuttithum of Mahidol University, Thailand; James Tartaglia of Sanofi; Abraham Pinter of Rutgers University; and Susan Zolla-Pazner of New York University.
The work was supported in part by the Center for HIV/AIDS Vaccine Immunology and the HIV-1 Vaccine Trials Network, both funded by the National Institute of Allergy and Infectious Diseases (U01 AI067854, 5U01 AI46725-05); and the U.S. Army Medical Research and Material Command.
Source: Duke Medicine